Evidence map›Paper›PMID 42992158›Full record

ArticleiLIVER2026

Thyroid-stimulating hormone-body mass index profile and mortality in metabolic dysfunction-associated steatotic liver disease.

Jie Xu, Jun-Zhe Yi, Ping Chen, Yu-Nan Zhang, Jiong-Liang Wang, Xin-Tong Wu, Yi-Min Zhang, Song Chen, Wei-Jie Wu, Zu-Qing Gao and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jie XuDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Jun-Zhe YiDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Ping ChenDepartment of VIP Region, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yu-Nan ZhangDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Jiong-Liang WangDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Xin-Tong WuDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yi-Min ZhangDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Song ChenDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Wei-Jie WuDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Zu-Qing GaoDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Zi-Xi Ou-YangDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Gen-Jun TanDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yu-Jia SongDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Hai-Jing DengDepartment of Pathology, State Key Laboratory of Liver Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Meng HeDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yi-Quan JiangDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Qi-Feng ChenDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Ming ZhaoDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Ning LyuDepartment of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Thyroid-stimulating hormone (TSH) and body mass index (BMI) are potential prognostic factors in metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated whether a combined TSH-BMI profile could refine risk stratification and identify lifestyle patterns associated with favorable outcomes in adults with MASLD. Methods: We analyzed 4,225 adults with MASLD from NHANES III, stratified into three age groups: young (<40 years; Results: Favorable ranges were TSH ≤ 1.4 mIU/L and BMI 24.5-27.5 kg/m Conclusion: The TSH-BMI profile may inform mortality risk assessment and identification of favorable lifestyle patterns in adults with MASLD.

Indexed as

Body mass indexLifestyle patternsMetabolic dysfunction-associated steatotic liver diseaseMortalityThyroid-stimulating hormone

Identifiers

PMID42992158
PMCPMC13738111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.